Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC30 in Type 2 Diabetes Mellitus
NCT07321678Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASC30 in type 2 diabetes mellitus (T2DM), sponsored by Ascletis Pharma Inc.. Started Jan 2026; status: completed.
02
Drugs
ASC30
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07321678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321678.